이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Impact of Peanut Consumption on Stress, Immune Function, Inflammation, and Cardiovascular Health in High-Stress Individuals

2026년 9월 8일 업데이트: USDA, Western Human Nutrition Research Center

Effects of Peanut Consumption on Physiological and Psychosocial Stress, Circulating Immune Cell Status, Markers of Inflammation and Cardiovascular Disease Risk, and Gastrointestinal Health in High-Stress Individuals

The purpose of this research is to determine whether peanut consumption improves indicators of cardiovascular disease (CVD) risk in human subjects following the consumption of study foods.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

The overall goal of the proposed study is to determine whether peanut consumption improves indices of cardiovascular disease (CVD) risk in human subjects with high levels of perceived chronic stress. Chronic stress is a growing public health concern and is associated with adverse health outcomes, including CVD. Stress, experienced when a person feels that environmental, physiological, or psychosocial demands tax or exceed their adaptive capacity, triggers a coordinated response from the sympathetic nervous system (SNS) and hypothalamic- pituitary- adrenal (HPA) axis increasing blood pressure, driving systemic inflammation, and affecting the immune system by accelerating the output of disease-promoting immune cells from bone marrow.

연구 유형

중재적

등록 (추정된)

70

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

  • 미국
    • California
      • Davis, California, 미국, 95616
        • 모병
        • Western Human Nutrition Research Center
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ryan Snodgrass, PhD
        • 부수사관:
          • Danielle Lemay, PhD
        • 부수사관:
          • Mary Kable, PhD
        • 부수사관:
          • Kevin Laugero, PhD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

설명

Inclusion Criteria:

  • Males and females
  • 18-65 years old
  • BMI ≥ 18.5 kg/m2 and ≤ 39.9 kg/ m2
  • Recruitment will be based on Perceived Stress Scale - 4 (PSS-4) score

Exclusion Criteria:

  • Less than 18 and over 65 years old
  • Pregnant or lactating women
  • Adults who rely on prescription medication that may influence study variables, apart from birth control
  • BMI < 18.5 kg/m2 and > 39.9 kg/m2
  • Smokers who currently use tobacco- or marijuana-containing products including e-cigarettes, vape pens, pod mods, tanks, and electronic nicotine delivery devices (ENDS)
  • Habitual consumption of nuts, nut butters, nut powders, nut side dishes, nut bars or other nut products
  • Known food allergies (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, sesame, corn) due to samples not prepared in a hypoallergenic environment
  • Currently living in close contact with individuals who have an allergy to peanuts, in order to avoid exposing these individuals to an allergen
  • Self-reported history of difficulties with blood drawing procedures including prior fainting or dizziness, or veins assessed as not suitable for four separate venipunctures by licensed phlebotomist

  • Diagnosed active chronic diseases for which the individual is currently taking daily medication, including but not limited to:

    • Diabetes mellitus, cardiovascular disease, cancer, gastrointestinal disorders, kidney disease, liver disease, bleeding disorders, asthma, autoimmune disorders, hypertension, osteoporosis
  • Recent minor surgery (within 4 weeks) or major surgery (within 16 weeks)
  • Known gallbladder disease or history of cholecystectomy
  • History of gastrointestinal surgery, including gastric bypass surgery or resection
  • Diagnosis of irritable bowel syndrome
  • Recent antibiotic therapy (within 4 weeks)
  • Recent hospitalization (within 4 weeks)
  • Current participation in another research study
  • Has HIV/AIDS, hepatitis, or another disease that affects the immune system
  • Gives regular blood donations and is unwilling to stop during the study
  • Blood Pressure ≥ 140 mmHg systolic or 90 mmHg diastolic
  • Current diagnoses of an eating disorder (ex. anorexia, bulimia, etc.)
  • High - very high triglyceride levels: ≥ 300 mg/dL
  • Adults who are unable to consent, individuals who are not yet adults (infants, children and teenagers), pregnant women and prisoners will be excluded from participation in the study
  • Participants who are unwilling to collect and transport urine, stool and saliva samples
  • Abnormal hemoglobin and/or hematocrit levels
  • Abnormal liver function (defined as liver enzymes that are >200% of upper limit (ALT upper limit is 43 U/L or Aspartate transaminase (AST) upper limit is 54 U/L)
  • Unwillingness to discontinue probiotic, prebiotic, fiber, or other supplements (except RDA-level vitamin and mineral supplements) during the study
  • Unwilling to consume study foods
  • Alcohol consumption > 20 g/day

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Peanut Intervention followed by corn chips Intervention
Participants will be asked to consume 42g of peanuts with skin daily for 4 weeks. Following a 4-week washout, the participant will then be asked to consume 45g of corn chips daily for 4 weeks.
다른: Peanuts, roasted, salted with skins
42g roasted salted peanuts with skins consumed daily
다른: Isocaloric food
Corn chips (45g)
실험적: Corn chip Intervention followed by Peanut Intervention
The participant will be asked to consume 45g of corn chips daily for 4 weeks. Following a 4-week washout, the participant will be then asked to consume 42g of peanuts with skin daily for 4 weeks.
다른: Peanuts, roasted, salted with skins
42g roasted salted peanuts with skins consumed daily
다른: Isocaloric food
Corn chips (45g)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in psychosocial stress over time
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks

The PSS-10 will be administered 4 times during the study. The 10-item Perceived Stress Scale (PSS-10) is a validated, standard instrument used to assess subjective perceptions of chronic psychological stress (i.e., excessive demands, insufficient coping resources, and a perceived lack of control).

The minimum score is 0 and the maximum score is 40. Higher scores indicate greater severity of psychosocial stress.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of allostatic load following dietary interventions
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Before and after each intervention, cumulative physiological stress load, also referred to as allostatic load (AL), will be calculated. AL will be derived from 12-h overnight urinary cortisol, norepinephrine, and epinephrine levels (corrected for urinary creatinine levels), resting systolic and diastolic blood pressure, and overnight fasted waist-to-hip ratio, fasting serum levels of high-sensitivity C-reactive protein (hs-CRP), cholesterol, HDL-cholesterol, fasting plasma dehydroepiandrosterone sulfate (DHEA-S), and whole blood glycohemoglobin (HbA1c).
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of monocyte gene expression
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Total monocytes isolated from human peripheral blood mononuclear cells (PBMCs) at baseline and post-intervention will be collected, and their global gene expression will be analyzed by ribonucleic acid (RNA) sequencing.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of cytokine and interferon production in PBMCs
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Monocytes isolated from human peripheral blood mononuclear cells (PBMCs) will be challenged with and without toll-like receptor ligands to assess cytokine and interferon production in low- and high-stress subjects at baseline and after intervention.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of cytotoxicity of peripheral natural killer cells
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
The cytotoxicity of peripheral natural killer (NK) cells isolated from subject's peripheral blood mononuclear cells (PBMCs) of low- and high-stress individuals at baseline and after intervention will be assessed using an ex vivo cytotoxicity assay with human erythroleukemic cell line (K562) target cells.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of interferon-gamma
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Interferon-gamma (IFN-γ) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of tumor necrosis factors alpha and beta
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Tumor necrosis factors alpha and beta (TNF-α, TNF-β) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of interleukins
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
A panel of interleukins: (IL) (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of fibroblast growth factor
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Fibroblast growth factor (FGF) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of granulocyte-macrophage colony-stimulating factor
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Granulocyte-macrophage colony-stimulating factor (GM-CSF) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery:
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of thymus and activation-regulated chemokine
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Thymus and activation-regulated chemokine (TARC). will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of macrophage inflammatory proteins-1 alpha and beta
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Macrophage inflammatory proteins-1 alpha and beta (MIP-1α, MIP-1β) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of macrophage-derived chemokine
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Macrophage-derived chemokine (MDC) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of monocyte chemoattractant proteins-1 and -4
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Monocyte chemoattractant proteins-1 and -4 (MCP-1, MCP-4) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of interferon gamma-induced protein-10
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Interferon gamma-induced protein-10 (IP-10) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of eotaxin and eotaxin-3
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Eotaxin and eotaxin-3 will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of C-reactive protein
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
C-reactive protein (CRP) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of intercellular adhesion molecule-1
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Intercellular adhesion molecule-1 (ICAM-1) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of placental growth factor
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Placental growth factor (PlGF) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of serum amyloid A
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Serum amyloid A (SAA) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of angiopoietin-1 receptor
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Angiopoietin-1 receptor (Tie-2) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of vascular cell adhesion molecule-1
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Vascular cell adhesion molecule-1 (VCAM-1) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of vascular endothelial growth factors A, C, and D
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Vascular endothelial growth factors A, C, and D (VEGF-A, VEGF-C, VEGF-D) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of vascular endothelial growth factor receptor-1
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of monocyte phenotype
기간: Baseline, 4 weeks, 8 weeks, 12 weeks
Classical monocytes, intermediate monocytes, and non-classical monocytes, will be identified by leukocyte common antigen (CD45+), Low-density lipoprotein receptor-related protein 1 (CD91+), cluster of differentiation 14 (CD14), cluster of differentiation 16 (CD16), and cluster of differentiation 3 (lin-CD3)/cluster of differentiation 66b (CD66b)/neural cell adhesion molecule (CD56)/cluster of differentiation 19 (CD19) using flow cytometry.
Baseline, 4 weeks, 8 weeks, 12 weeks
Change from baseline of monocyte functional profile
기간: Baseline, 4 weeks, 8 weeks, 12 weeks
Cellular activation of classical monocytes, intermediate monocytes, and non-classical monocytes will be assessed by expression of cluster of differentiation 11b (CD11b) and cluster of differentiation 163 (CD163).
Baseline, 4 weeks, 8 weeks, 12 weeks
Change from baseline of natural killer cell phenotype
기간: Baseline, 4 weeks, 8 weeks, 12 weeks
Natural killer (NK) cells will be identified by CD45+, cluster of differentiation 56+ (CD56+), and lin-CD3/CD66b/CD14/CD19 using flow cytometry.
Baseline, 4 weeks, 8 weeks, 12 weeks
Change from baseline of natural killer cell functional profile
기간: Baseline, 4 weeks, 8 weeks, 12 weeks
Natural killer (NK) cell maturation status and cytotoxic potential via CD16, cluster of differentiation 57 (CD57), killer cell lectin-like receptor K1 (NKG2D), and cluster of differentiation 159 (NKG2A) will be analyzed using flow cytometry.
Baseline, 4 weeks, 8 weeks, 12 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Changes in stool consistency
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Participants will provide stool samples at 4 times throughout the study. Stool samples will be used to confirm the stool consistency reported by the study subject.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Changes in stool metrics
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Participants will provide stool samples at 4 times throughout the study. Stool samples will be used to determine the whole stool weight.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Changes in bowel movement frequency
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
During the week prior to each intervention and the final week of each intervention, participants will maintain a stool diary for recording frequency of bowel movements.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Changes in Gastrointestinal (GI) symptoms
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
During the week prior to each intervention and the final week of each intervention, a short GI Symptoms Questionnaire will be administered via Qualtrics to record occurrence of gastric symptoms.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Changes in gut microbial diversity
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Participants will provide stool samples at 4 times throughout the study. Stool samples will be used to determine the microbial community composition by 16-subunit ribosomal ribonucleic acid (16S rRNA) amplicon sequence analysis.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Changes in stool short chain fatty acids
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Participants will provide stool samples at 4 times throughout the study. Stool samples will be used to measure the amount of fecal short chain fatty acids (SCFAs).
Baseline, 4 weeks, 8 weeks, and 12 weeks
Changes in gut inflammatory markers
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Participants will provide stool samples at 4 times throughout the study. Stool samples will be used to measure the inflammatory marker, fecal calprotectin.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in salivary cortisol
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks

To assess waking and diurnal cortisol fluctuations, saliva will be collected at home at selected times upon waking and before bedtime. The waking saliva sample must be collected within 10-15 minutes of waking. Following the waking sample, participants will be asked to collect additional saliva samples at 15, 30, 45, and 60 minutes after the waking sample, as well as a saliva sample before bedtime.

In total, participants will return 24 saliva samples (6 per visit) throughout the study.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in urinary cortisol levels
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Before and after each intervention, 12-hour overnight urinary cortisol will be measured.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in urinary epinephrine levels
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Before and after each intervention, 12-hour overnight urinary epinephrine levels will be measured.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in urinary norepinephrine levels
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Before and after each intervention, 12-hour overnight urinary norepinephrine levels will be measured.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in urinary creatinine levels
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Before and after each intervention, 12-hour overnight urinary creatinine levels will be measured.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in resting blood pressure
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Research team will collect resting blood pressure (systolic and diastolic) in mmHg (millimeters of mercury).
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in dietary intake
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Dietary intake will be assessed by using the Automated Self-Administered 24-hour (ASA24®) dietary assessment tool, a web-based tool that enables multiple, automatically coded, self-administered 24-hour recalls. Three dietary recalls will be conducted in the week preceding and the final week of each intervention period, for a total of 12, 24-hour dietary recalls.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in Body Weight
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Research team will collect weight in kg.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in white blood cell count
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
White blood cell (WBC) count will be measured by a DxH 520 Hematology analyzer.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in lymphocyte count
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Lymphocyte (LY) count will be measured by a DxH 520 Hematology analyzer.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in monocyte count
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Monocyte (MO) count will be measured by a DxH 520 Hematology analyzer.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in neutrophil granulocyte count
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Neutrophil granulocyte (NE) count will be measured by a DxH 520 Hematology analyzer.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in eosinophil count
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Eosinophil (EO) count will be measured by a DxH 520 Hematology analyzer.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in basophil count
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Basophil (BA) count will be measured by a DxH 520 Hematology analyzer.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in levels of triglycerides
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Lipid-related markers including triglycerides will be measured by auto-analyzer, Cobas Integra 400+ instrument.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in levels of total cholesterol
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Lipid-related markers including total cholesterol will be measured by auto-analyzer, Cobas Integra 400+ instrument.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in levels of HDL-cholesterol
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Lipid-related markers including HDL-cholesterol (HDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in levels of LDL-cholesterol
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Lipid-related markers including LDL-cholesterol (LDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Change in levels of glucose
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
Plasma glucose will be measured by auto-analyzer, Cobas Integra 400+ instrument.
Baseline, 4 weeks, 8 weeks, and 12 weeks
Changes in gut transit time
기간: Baseline, 4 weeks, 8 weeks, and 12 weeks
During the week prior to each intervention and the final week of each intervention, participants will consume a muffin containing blue food dye. Participants will log the date and time of consumption, and will log each bowel movement until stool color changes. This will be used to measure gut transit time.
Baseline, 4 weeks, 8 weeks, and 12 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

USDA, Western Human Nutrition Research Center

수사관

  • 수석 연구원: Ryan Snodgrass, PhD, United States Department of Agriculture - Western Human Nutrition Research Center

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 9월 1일

기본 완료 (추정된)

2028년 8월 1일

연구 완료 (추정된)

2028년 8월 1일

연구 등록 날짜

최초 제출

2025년 8월 4일

QC 기준을 충족하는 최초 제출

2026년 7월 24일

처음 게시됨 (실제)

2026년 7월 29일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 11일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 8일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 2280324

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다